key: cord-0757488-wtfgn83w
authors: GOMEZ, J.; CUESTA-LLAVONA, E.; ALBAICETA, G. M.; GARCIA-CLEMENTE, M.; LOPEZ-LARREA, C.; AMADO, L.; LOPEZ-ALONSO, I.; HERMIDA, T.; ENRIQUEZ, A.; GIL, H.; ALONSO, B.; IGLESIAS, S.; SUAREZ-ALVAREZ, B.; ALVAREZ, V.; COTO, E.
title: The CCR5-delta32 variant might explain part of the association between COVID-19 and the chemokine-receptor gene cluster
date: 2020-11-04
journal: nan
DOI: 10.1101/2020.11.02.20224659
sha: 8d3618b5958052c65a84fba0f898a9cc390e865b
doc_id: 757488
cord_uid: wtfgn83w

A polymorphism in the LZTFL1 gene located in the chemokine-receptor gene cluster (chromosome 3p) has been associated with the risk of developing COVID-19. The chemokine receptor-5 (CCR5) maps to this region, and the common 32 bp deletion variant ({Delta}32) has been associated with the extent of inflammatory disease and the outcome in several viral diseases. Several studies have also suggested that the pharmacological targeting of CCR5 could reduce the impact of SARS-CoV-2 infection and the severity of COVID-19. We sought to investigate whether this polymorphism was associated with the risk of moderate-severe COVID-19. We genotyped 294 patients who required hospitalization due to COVID-19 (85 were severe cases) and 460 controls. We found a significantly lower frequency of CCR5-{Delta}32 among the COVID-19 patients (0.10 vs 0.18 in controls; p=0.002, OR=0.48, 95%CI=0.29-0.76). The difference was mainly due to the reduced frequency of CCR5-{Delta}32 carriers in the severe, significantly lower than in the non-severe patients (p=0.036). Of note, we did not find deletion-homozygotes among the patients compared to 1% among controls. We also confirmed the association between a LZTFL1 variant and COVID-19. Our study points to CCR5 as a promising target for treatment of COVID-19, but requires validation in additional large cohorts. In confirmed by others, the genetic analysis of CCR5-variants (such as {Delta}32) might help to identify patients with a higher susceptibility to severe COVID-19.

The clinical spectrum of COVID-19 varies from none or very mild-symptoms to moderate symptoms that required hospitalization, and in some cases severe pneumonia and acute respiratory distress syndrome (ARDS) that requires mechanical ventilation and admission into intensive care unit (ICU). An exacerbated immune response A recent study showed a beneficial effect of leronlimab (a CCR5 blocking antibody) on a reduced group of severe COVID-19 patients (Patterson et al., 2020) . These patients showed a significant reduction of the SARS-Cov-2 viral load, with a rapid reduction of plasma IL-6 and restoration of the CD4/CD8 ratio. In another study a total of 23 hospitalized severe/critical COVID-19 patients received leronlimab subcutaneously (Yang et al., 2020) . By day 30 after initial dosing Leronlimab was safe and well tolerated, 17/23 were recovered and 4/23 had died. The authors concluded that those with lower inflammatory markers had better outcomes, with IL-6 tending to fall overtime. Cenicriviroc (CVC) is a CCR5 antagonist with potent and selective antihuman immunodeficiency virus type 1 (HIV-1) activity. CVC showed anti SARS-Cov-2 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 activity by inhibition of virus-induced cell destruction and reduction of the viral RNA levels in culture supernatants of infected cells (Okamoto et al., 2020).

CCR5 is the receptor for HIV entry into the host cells, and a common variant that abrogates its expression in homozygotes (the 32 bp deletion, Δ 32) is associated with the resistance to AIDS among HIV-exposed (Kou and Kuang, 2019). Approximately 1% of Europeans are The first COVID-19 Genome Wide Association study (GWAs) reported a strong association with chromosome 3 variants in the chemokine-receptor cluster (Ellinghaus et al., 2020). CCR5 maps to this region and could thus partly explain the observed association with polymorphisms in the chemokine-receptor cluster. We sought to investigate whether CCR5-Δ32 was associated with the risk of developing or was a genetic modifier of disease severity.

The study was based on 294 patients who required hospitalization due to COVID-19 (mean age 64.77 years, range 24-95) and 460 population age-matched controls (mean age 70.01 years, range 50-81). All the study participants were Caucasian from the region of Asturias (Northern Spain, total population 1 million). Severe cases (n=85) were defined as those in need of critical care support, including high-flow oxygen, positive-pressure ventilation (either invasive or non-invasive) or vasoactive drugs. The presence of comorbidities (hypertension, diabetes, hypercholesterolaemia) was obtained from the participants medical records. The study was approved by the Ethics Committee For this SNP the PCRs were digested with the restriction enzyme MspI and the allele-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. 

The main finding of our study was a significantly lower frequency of CCR5-Δ32 among the COVID-19 patients (table 1). Multiple logistic regression with age, sex and hypertension showed that in our population carriers of the 32 bp deletion were significantly less frequent among the patients (30/294=0.10 vs 85/460=0.18 in controls;

p=0.002, OR=0.48, 95%CI=0.29-0.76). The difference was mainly due to the reduced frequency of CCR5-Δ32 carriers in the severe-ICU group, significantly lower than in the non-severe patients (p=0.036). Of note, we did not find deletion-homozygotes among the patients compared to 1% among controls. Carriers of the deletion would express less membrane-bound receptor and an attenuated pro-inflammatory response Because CCR5 is not a recognised receptor for SARS-Cov-2 the most likely explanation for the protective effect of Δ 32 in COVID-19 is an attenuated inflammatory response among the CCR5-deletion carriers. This finding was in agreement with a report that showed that mice lacking CCR5 infected with a neurotropic coronavirus showed an attenuated inflammatory response, with reduced macrophage infiltration and demyelination (Glass et al., 2001) .

We confirmed the association between LZTFL1 (SNP rs67959919) and the risk of All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224659 doi: medRxiv preprint COVID-19. LZTFL1 variants were associated with COVID-19 in a GWAs including participants from Italy and Spain. In our cohort the rare T-allele was associated with an increased risk of COVID-19 after correcting by age, sex and hypertension (P=0.003, OR=1.86 (1.23-2.82), but we did not find significant difference between severe and non-severe cases ( Table 1) . We calculated the Δ 32 -rs67959919 haplotype frequencies in patients and controls (table 2). The rs67959919 A -CCR5 non-deletion (wild-type) haplotype was significantly more common among the patients (p<0.001, OR=2.01, 95%CI=1.45-2.79). We cannot exclude that the association between one of the variants was a consequence to its linkage-disequilibrium (LD) with the other, or with some not yet identified variant in the chemokine-receptor cluster. Multiple logistic regression with the two genotypes were independent predictors of COVID-19: CCR5-Δ32 carriers, p=0.005, OR=0.52 (95%CI=0.33-0.81); rs67959919-A carriers, p=0.024, OR=1.56 (95%CI=1.06-2.31).

The main limitation of our study was the reduced size of the patient´s cohort. However, our results were in agreement with the reported association between chromosome 3p21.31 variants and COVID-19. In this way, the association between CCR5-Δ32 and COVID-19 seems plausible and deserves further validation in larger cohorts. If confirmed, the CCR5 variants might serve as valuable markers to identify individuals predisposed to severe COVID-19. A limitation was also that we did not provide a functional link between the CCR5 deletion and COVID-19 outcomes, and we cannot conclude whether this variant was associated with an overall resistance to SARS-Cov-2 infection or a reduced inflammatory response, or both. Although the CCR5 has not a recognised role in SARS-CoV-2 binding to the host cell, a preliminary study showed that the CCR5 inhibitor Maraviroc was able to decrease the extent of viral-cell fusion Finally, the pharmacological blockade of CCR5 has been associated with an improvement of the symptoms in a group of severe COVID-19 patients. In a limited study involving 10 patients the anti-CCR5 antibody Leronlimab showed an improvement of disease symptoms, with a rapid reduction of plasma IL-6 and restoration of the CD4/CD8 ratio and a significant reduction of the SARS-Cov-2 viral All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224659 doi: medRxiv preprint load (Patterson et al., 2020) . Also, in-vitro studies with SARS-Cov-2 infected cells showed that the CCR5 antagonist Cenicriviroc had potent anti-viral activity by inhibition of virus-induced cell destruction and reduction of the viral RNA levels (Okamoto et al., 2020) . These and other studies pointed to CCR5 as a potential target for COVID-19 treatment. The genetic analysis of CCR5-variants, such as Δ 32, might help to identify patients with a higher susceptibility to severe COVID-19.

Contributorship. All the authors contributed to this work by recruiting the patients and performing the genetic and statistical analysis. E.C. wrote the ms. and takes full responsibility for the accuracy of the data. All the authors approved the submission of this ms.

To facilitate the revision of our results by other researchers, an excel file with the data is provided as supplementary file.

Acknowledgements. This work was supported by a grant from the Spanish Plan Nacional de I+D+I Ministerio de Economía y Competitividad and the European FEDER, grant ISCIII-Red de Investigación Renal-REDINREN RD16/9/5 (EC).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224659 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224659 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224659 doi: medRxiv preprint 1 3 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. ; https://doi.org/10.1101/2020.11.02.20224659 doi: medRxiv preprint Figure 2 . Sequence electropherograms (above) and gel electrophoresis of PCR fragments (below) corresponding at the three CCR5 32 bp deletion. The DNA was amplified with CTGTGTTTGCGTCTCTCCCA and CCTCTTCTTCTCATTTCGACAC, and the PCRs electrophoresed on a 4% agarose gel to visualise the alleles as fragments of 222 bp (wildtype) and 190 bp (Δ32).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 4, 2020. ; https://doi.org/10. 1101 

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.Front Immunol

The Expanding Therapeutic Perspective of CCR5 Blockade

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab

Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit Care

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity